Elahere
Biological
ImmunoGen, Inc.
Total Payments
$4.3M
Transactions
3,129
Doctors
1,706
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $4.3M | 3,129 | 1,706 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.6M | 282 | 84.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $298,027 | 93 | 7.0% |
| Consulting Fee | $145,267 | 62 | 3.4% |
| Food and Beverage | $101,117 | 2,450 | 2.4% |
| Travel and Lodging | $78,982 | 235 | 1.8% |
| Grant | $24,750 | 7 | 0.6% |
Payments by Type
Research
$3.6M
282 transactions
General
$648,142
2,847 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MIRV/BEV serous endometrial cancer | ImmunoGen, Inc. | $1.4M | 0 |
| MIRV/carboplatin neo-adjuvant therapy in newly diagnosed ovarian cancer | ImmunoGen, Inc. | $908,300 | 0 |
| A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO) | ImmunoGen, Inc. | $448,807 | 0 |
| Single agent MIRV in high grade serous endometrial cancer | ImmunoGen, Inc. | $259,050 | 0 |
| MIRV olaparib in 2nd line PSOC | ImmunoGen, Inc. | $248,800 | 0 |
| Multicenter, Open-label, ph 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRa Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy | ImmunoGen, Inc. | $200,208 | 0 |
| A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRa Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers | ImmunoGen, Inc. | $139,033 | 0 |
| SORAYA: A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | ImmunoGen, Inc. | $54,871 | 0 |
| MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression | ImmunoGen, Inc. | $5,000 | 0 |
Top Doctors Receiving Payments for Elahere — Page 69
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Obstetrics & Gynecology | Neptune, NJ | $12.86 | 1 |
| , CNP | Family | Pierre, SD | $12.82 | 1 |
| Teddi Dowling | Nurse Practitioner | Pierre, SD | $12.82 | 1 |
| , MD | Internal Medicine | Brooklyn, NY | $12.71 | 1 |
| , MD | Internal Medicine | Brooklyn, NY | $12.71 | 1 |
| , MD | Internal Medicine | Brooklyn, NY | $12.71 | 1 |
| , M.D | Hematology & Oncology | Brooklyn, NY | $12.71 | 1 |
Ad
Manufacturing Companies
- ImmunoGen, Inc. $4.3M
Product Information
- Type Biological
- Total Payments $4.3M
- Total Doctors 1,706
- Transactions 3,129
About Elahere
Elahere is a biological associated with $4.3M in payments to 1,706 healthcare providers, recorded across 3,129 transactions in the CMS Open Payments database. The primary manufacturer is ImmunoGen, Inc..
Payment data is available from 2023 to 2023. In 2023, $4.3M was paid across 3,129 transactions to 1,706 doctors.
The most common payment nature for Elahere is "Unspecified" ($3.6M, 84.8% of total).
Elahere is associated with 9 research studies, including "MIRV/BEV serous endometrial cancer" ($1.4M).